Total Payments
$403,469
2024 Payments
$20,245
Companies
11
Transactions
81
Payment Breakdown by Category
Research$394,750 (97.8%)
Travel$4,095 (1.0%)
Consulting$3,500 (0.9%)
Food & Beverage$1,124 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $394,750 | 43 | 97.8% |
| Travel and Lodging | $4,095 | 14 | 1.0% |
| Consulting Fee | $3,500 | 1 | 0.9% |
| Food and Beverage | $1,124 | 23 | 0.3% |
Payments by Type
Research
$394,750
43 transactions
General
$8,719
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Endo Pharmaceuticals Inc. | $189,493 | 9 | $0 (2018) |
| Overseas Pharmaceuticals LLC | $166,355 | 2 | $0 (2023) |
| Eli Lilly and Company | $26,815 | 5 | $0 (2024) |
| Allergan, Inc. | $6,323 | 14 | $0 (2021) |
| Noven Therapeutics, LLC | $4,353 | 5 | $0 (2020) |
| PFIZER INC. | $3,237 | 3 | $0 (2023) |
| Merck Sharp & Dohme LLC | $3,181 | 29 | $0 (2023) |
| Noven Pharmaceuticals, Inc. | $2,032 | 2 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $1,479 | 8 | $0 (2017) |
| ABBVIE INC. | $156.32 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,245 | 2 | Eli Lilly and Company ($20,200) |
| 2023 | $12,504 | 7 | Overseas Pharmaceuticals LLC ($8,182) |
| 2022 | $158,354 | 5 | Overseas Pharmaceuticals LLC ($158,173) |
| 2021 | $1,141 | 3 | Allergan, Inc. ($1,141) |
| 2020 | $5,526 | 15 | Noven Therapeutics, LLC ($4,353) |
| 2019 | $1,948 | 17 | Merck Sharp & Dohme Corporation ($1,948) |
| 2018 | $192,322 | 10 | Endo Pharmaceuticals Inc. ($189,493) |
| 2017 | $11,429 | 22 | Allergan Inc. ($5,182) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $44.86 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $20,200.21 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | ||||||
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,078.99 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,078.99 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/30/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,078.99 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/17/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/04/2023 | Overseas Pharmaceuticals LLC | — | — | Cash or cash equivalent | $8,182.10 | Research |
| Study: A Randomized, Double-Blind, Parallel-Arm Study Comparing the Efficacy of Investigational Product Ibuprofen Modified-Release Tablets 800 mg and Placebo in Patients with Chronic Pain Related to Osteoarthritis of the Knee. | ||||||
| 06/05/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | ||||||
| 05/03/2023 | Eli Lilly and Company | — | — | In-kind items and services | $514.59 | Research |
| Study: A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | ||||||
| 11/22/2022 | Overseas Pharmaceuticals LLC | — | — | Cash or cash equivalent | $158,173.14 | Research |
| Study: A Randomized, Double-Blind, Parallel-Arm Study Comparing the Efficacy of Investigational Product Ibuprofen Modified-Release Tablets 800 mg and Placebo in Patients with Chronic Pain Related to Osteoarthritis of the Knee. | ||||||
| 07/19/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: VACCINE | ||||||
| 02/23/2022 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $113.52 | Research |
| Study: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine • Category: FACIAL AESTHETICS | ||||||
| 02/23/2022 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $26.00 | Research |
| Study: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine • Category: FACIAL AESTHETICS | ||||||
| 02/23/2022 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $16.80 | Research |
| Study: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine • Category: FACIAL AESTHETICS | ||||||
| 09/18/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $188.86 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2021 | Allergan, Inc. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $715.60 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2021 | Allergan, Inc. | BOTOX (Biological) | Travel and Lodging | In-kind items and services | $236.17 | General |
| Category: NEUROSCIENCE | ||||||
| 02/07/2020 | Noven Therapeutics, LLC | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 02/07/2020 | Noven Therapeutics, LLC | — | Travel and Lodging | Cash or cash equivalent | $740.71 | General |
| 02/07/2020 | Noven Therapeutics, LLC | — | Food and Beverage | In-kind items and services | $89.52 | General |
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Travel and Lodging | In-kind items and services | $69.66 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $49.60 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $49.58 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | In-kind items and services | $34.71 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | GARDASIL 9 (Biological) | Food and Beverage | Cash or cash equivalent | $29.19 | General |
| Category: VACCINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | Endo Pharmaceuticals Inc. | $189,493 | 9 |
| A Randomized, Double-Blind, Parallel-Arm Study Comparing the Efficacy of Investigational Product Ibuprofen Modified-Release Tablets 800 mg and Placebo in Patients with Chronic Pain Related to Osteoarthritis of the Knee. | Overseas Pharmaceuticals LLC | $166,355 | 2 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | Eli Lilly and Company | $20,735 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $3,681 | 7 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $3,237 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | Eli Lilly and Company | $2,829 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $2,736 | 1 |
| A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HP-5000 IN SUBJECTS WITH OSTEOARTHRITIS OA OF THE KNEE. | Noven Pharmaceuticals, Inc. | $2,032 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $1,501 | 4 |
| Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip | Regeneron Pharmaceuticals, Inc. | $1,479 | 8 |
| A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | Eli Lilly and Company | $514.59 | 1 |
| Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine | ABBVIE INC. | $156.32 | 3 |
About Dr. James Clark, MD
Dr. James Clark, MD is a Internal Medicine healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1407900400.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Clark, MD has received a total of $403,469 in payments from pharmaceutical and medical device companies, with $20,245 received in 2024. These payments were reported across 81 transactions from 11 companies. The most common payment nature is "" ($394,750).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Charlottesville, VA
- Active Since 01/23/2007
- Last Updated 04/29/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1407900400
Products in Payments
- ZAVZPRET (Drug) $3,237
- V114 (Biological) $1,948
- BOTOX (Biological) $1,297
- GARDASIL 9 (Biological) $1,173
- CAPVAXIVE (Biological) $24.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Charlottesville
Ellen Volker, Md, MD
Internal Medicine — Payments: $175,175
Internal Medicine $175,175
Dr. Oliver Monfredi, Md, MD
Internal Medicine — Payments: $81,756
Internal Medicine $81,756
Ryan Gentzler, M.d, M.D
Internal Medicine — Payments: $76,633
Internal Medicine $76,633
Dr. Mirnela Byku, Md, MD
Internal Medicine — Payments: $58,728
Internal Medicine $58,728
Jonathan Lindner, Md, MD
Internal Medicine — Payments: $56,108
Internal Medicine $56,108
Dr. Amy Mathers, M.d, M.D
Internal Medicine — Payments: $33,419
Internal Medicine $33,419